Kurt J. Hilzinger, CPA
Kurt Hilzinger joined the Claritas Rx Advisory Board in January 2016. He is currently a Partner with Court Square Capital Partners, a private equity firm based in New York City, where he is focused on making investments in the healthcare industry. Since 2003, Mr. Hilzinger has also been on the board of managed care company, Humana, including serving as lead director from 2010 to 2014 when he became chairman of the Board.
Previously, Mr. Hilzinger served as President and Chief Operating Officer and earlier as Executive Vice President and Chief Financial Officer of AmerisourceBergen Corporation, one of the worlds’ largest pharmaceutical services companies serving the United States, Canada and related global markets. He has also served on the board of AmerisourceBergen as well as Chairman of the Healthcare Distribution Management Association (HDMA). In addition he has served as Chairman of the Harvard Drug Group, Inc., and on the boards of Western Dental, Arizant Healthcare, Inc. and Physiotherapy Associates.
In addition, Mr. Hilzinger also currently serves on the Board of NDC, Inc. (a Court Square portfolio company), the Board of Directors of Oncobiologics, Inc., the Board of the Presidential Advisors at Thomas Jefferson University and Healthcare System, and the Visiting Committee at the Ross School of Business at the University of Michigan. He received his B.B.A. degree from the University of Michigan and is a certified public accountant.
Kent Lieginger, Pharm.D.
Kent Lieginger joined the Claritas Rx Advisory Board in January 2016. He currently serves on Achaogen’s board of directors and has most recently served as Senior Vice President, Managed Care and Customer Operations at Genentech, Inc., as well as Director of the Genentech Foundation since 2005. He originally joined Genentech as Vice President, Managed Care and Customer Operations in 2004 and served as a member of Genentech’s Commercial Leadership Committee. Prior to joining Genentech, Dr. Lieginger was Vice President, National Insurer and Employer Segment (Managed Markets Division) at GlaxoSmithKline plc, where he also led teams in U.S. and global business development, finance, strategic contracting, manufacturing, marketing, and sales.
Dr. Lieginger completed his residency in clinical pharmacy at the University of California in San Francisco, served for four years as Assistant Clinical Professor of Medicine at the University of California, Davis School of Medicine, and has served on the Board of Trustees at University of the Sciences in Philadelphia since 2013.